TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Success Rate on Investigator's Global Assessment (IGA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Change in NonInflammatory Lesion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Odds ratio for association with risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of undernutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: bioavailability of Mycophenolate mofetil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of cancer cells in peritoneal washings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Plasma concentrations of choline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma concentrations of betaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma concentrations of phosphocholine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Events and circumstances of Homologous Blood Transfusion
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum concentration (Cmax) of E4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve from time 0 to the last determined concentration (AUC0-tdlc) of E4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve from time 0 to infinity (AUC0-inf) of E4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with a bacteraemia
Endpoint domain: Adverse events/effects
Primary endpoint: ADAS-Cog-11 Score Change
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: ADCS-ADL Score Change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximum Tolerated Dose (MTD) of Orally Administered PLB1004
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Recommended Phase II Dose (RP2D) of Orally Administered PLB1004
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Length of the operating procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Ocular comfort after 6 hours of contact lens wear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dryness sensation after 6 hours of contact lens wear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tear film volume before and after 6 hours of contact lens wear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of LigaSure Device in destroying tubal cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) associated with dose-limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with failed treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Death/ARDS or Septic shock
Endpoint domain: Mortality/survival
Primary endpoint: Onset of Immediate Postoperative Delirium
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under Plasma Concentration-time Curve (AUC[0-t])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal Phase Half-life (T1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steatosis evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Fibrosis evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Change in primary protease inhibitor mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient perception of complementary and alternative medicines
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall Survival (24-month Rate)
Endpoint domain: Mortality/survival
Primary endpoint: Lingual tonsil enlargement grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extracellular volume (MRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myocardial stiffness (p-v-loops)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnostic accuracy of Calprotectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dental Discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Complication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Neurocognitive test domain scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Knee calcification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of subjects with ocular adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Responder rate after deployment of valves
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Recurrence of Atrial Arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to Treatment for Recurrence of Atrial Arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Intervention and Control Group Patients Treated for Recurrent Atrial Arrhythmia
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum tolerated dose (MTD) as determined by dose limiting toxicity (DLT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean Change in Psychopathology as measured by PANSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Psychopathology as measured by PSYRATS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Insight Scores as measured by SUMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Insight Scores as measured by BCIS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Metacognition Scores as measured by MAS-A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent vitreous hemorrhage rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Cilia length in human airway epithelial
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Alterations in leukocyte DNA methylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in perceived deficiencies score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: half life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean blood glucose concentration during mixed-meal tolerance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total score of the Yale-Brown Obsessive Compulsive Scale (Y-BOCS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in total sleep time
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: HADS Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HADS Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bone mineral density (BMD) at hip and spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chorioretinal perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perfusion of the neovascular net (CNV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central visual function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of sinus bradycardia or atrioventricular block requiring hemodynamic intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Metaphase 2 oocyte number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of patients longitudinally monitored
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Excellent outcome at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: sedation degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endoscopist´s and patient´s satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pregnancy outcome (spontaneous miscarriage versus evolutive pregnancy)
Endpoint domain: Mortality/survival
Primary endpoint: Identification rates of sentinel lymph node biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement in Hearing Thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Chemoresistance defined by clinical recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Chemoresistance defined by biological recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Chemoresistance defined by radiological recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Target identification success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of patients requiring colectomy
Endpoint domain: Adverse events/effects
Primary endpoint: Change in extent of iris neovascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Proportion of subjects progressing to endotracheal intubation or death
Endpoint domain: Mortality/survival
Primary endpoint: Change of Clinical Attachment Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of beta-carotene
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of [13C]retinol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Secretion function of the pancreas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Predict malignancy in mediastinal lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Presence of Central Sensitization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight trajectory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: RDS evolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence and severity of common cold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Knowledge, Self-efficacy, and Habit Formation Survey score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of restored uterine cavity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of Cases Where FFR Data Results in a Change in Management Strategy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in cognitive testing results
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of patients initiated on recommended therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Periapical periodontium health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: objective image quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: military task performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: WOMAC changes at 12 weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: symptomatic occurrence of major and clinical relevant bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical evaluation of restoration quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure of resection of large colon polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Intensive Care Unit (ICU) Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Berg-Balance Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Physical Activity Questionnaire - Short form
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in evening pre-dose FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Unified Huntington's Disease Rating Scale (UHDRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Malnutrition scored with NRS 2002 questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Malnutrition scored with SGA questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receipt of planned therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in the Endotracheal Tube Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in Nurses Work Load
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to completion of laparoscopic tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Visual Acuity over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Non-serious Adverse Events (nSAEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Electrocardiogram (ECG) Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients who develop scintigraphy limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in healthcare associated infections (CRBSI and VAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: genomic DNA in culture medium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Solicited Symptoms After Dose 1
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After Dose 1
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Medically-Attended Lower Respiratory Illnesses (MA-LRIs) After Dose 1
Endpoint domain: Adverse events/effects
Primary endpoint: Brain activity including microsleeps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Participants' fatigue and drowsiness level while driving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of IDH1/2 mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Heavy Metal Urine Analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Reporting Treatment Emergent Local Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: health benefit for patients with bladder cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants recruited after 12 months
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of exercise classes attended at trial completion (6 months)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: End-tidal carbon monoxide levels corrected for ambient air (ETCOc)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Serum sample array compilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dermal blood flow measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total Complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: Change in BMI z Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Parent Resource Empowerment
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Produce intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Glucose Infusion Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Epidural wave form reliability (sensitivity, specificity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Lumbar Spine BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: Length of Pregnancy Prolongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Overall Change in Forced Vital Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Scores of the PROMIS Cognitive Function, short form 8a
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Scores of the Self-Administered Gerocognitive Exam (SAGE)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Scores of the Montreal Cognitive Assessment (MoCA)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: number of days with headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Achieving Attack-Free Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: AUCt - Area under the serum concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC∞ - Area under the serum concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax - Maximum serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: St Hans Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: BPRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: remission of type 2 diabetes mellitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Onset of labor type (spontaneous vs induced)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: change of dose site appearance
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of responder patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of Fraction of Exhaled Nitric Oxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sarcopenia diagnosis accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically Significant Hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: Difference of Visual Analog Score for pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Difference of SF-36 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: toxicity of tandem PBSC rescue
Endpoint domain: Adverse events/effects
Primary endpoint: Change in lumbo-pelvic stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Venlafaxine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Toxicity associated with oxandrolone therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Knee prosthesis rotational alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Knee prosthesis translational alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Delay discounting score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of minutes of moderate physical activity per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint Stiffness of affected upper limb joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Progression-Free Survival at 18 Weeks
Endpoint domain: Mortality/survival
Primary endpoint: Progression-Free Survival Based on Radiologic and Clinical Assessments
Endpoint domain: Mortality/survival
Primary endpoint: Absence of persistent epithelial defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Muscle Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time-to-treatment initiation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of oral mucositis of grade 2 or higher
Endpoint domain: Adverse events/effects
Primary endpoint: Type, frequency, severity, seriousness and relatedness of adverse events
Endpoint domain: Adverse events/effects